Reuters logo
BRIEF-Neurocrine Biosciences announces FDA advisory committee meeting to review Ingrezza NDA
November 29, 2016 / 9:35 PM / a year ago

BRIEF-Neurocrine Biosciences announces FDA advisory committee meeting to review Ingrezza NDA

Nov 29 (Reuters) - Neurocrine Biosciences Inc

* Neurocrine announces FDA advisory committee meeting to review Ingrezza (valbenazine) new drug application for the treatment of tardive dyskinesia

* FDA has granted priority review status to Ingrezza NDA with a PDUFA target action date of April 11, 2017 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below